Li Dean Y's Form 4/A amendment
AmendedRecursion Pharmaceuticals, Inc. (RXRX) · filed Dec 9, 2021
- Accession no.
- 0001209191-21-068911
- Filed
- Dec 9, 2021
- Trade date
- Nov 17-19, 2021
- Filing delay
- 22 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
- Original filed
- Nov 19, 2021
This filing lists 2 non-derivative transactions. Open-market sales total $384.9K. It was filed 22 days after the trade.
This amendment replaces 0001209191-21-065896 (filed Nov 19, 2021).
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Li Dean YCIK 0001837016 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Sales are pursuant to a 10b5-1 trading plan established by the Reporting Person.
- F2
The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $20.00 to $20.13 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request.
Referenced by the price of 1 transaction in Table I.
- F3
The Form 4 filed on November 19, 2021 inadvertently attributed the reported transaction to the incorrect holding. The original Form 4 attributed the reported transaction to the reporting person's direct holding, while the reported transaction should have been attributed to the reporting person's indirect holding by the Dean Y. Li 2021 GRAT.
- F4
The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $20.00 to $20.26 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request.
Referenced by the price of 1 transaction in Table I.